What is claimed is:

1. Use of a first pharmaceutical therapy and a second pharmaceutical therapy in the manufacture of a medicament for the treatment of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) in a patient in need thereof, wherein the first pharmaceutical therapy comprises a nuclease-resistant polynucleotide that hybridizes to a Grb2 nucleic acid and inhibits Grb2 expression, and wherein the second pharmaceutical therapy comprises decitabine.

2. The use of claim 1, wherein the polynucleotide hybridizes to the translation initiation site of a Grb2 nucleic acid.

3. The use of either claim 1 or 2, wherein the polynucleotide is an oligonucleotide having a length of 8-50 bases.

4. The use of any one of claims 1-3, wherein the polynucleotide has a sequence according to SEQ ID NO: 1.

5. The use of any one of claims 1-4, wherein the polynucleotide comprises P-ethoxy backbone linkages.

6. The use of any one of claims 1-5, wherein the polynucleotide is encapsulated in a liposome.

7. The use of any one of claims 1-6, wherein the first pharmaceutical therapy further comprises a neutral lipid.

8. The use of any one of claims 1-7, wherein the first pharmaceutical therapy is to be administered systemically.

9. The use of any one of claims 1-8, wherein the first pharmaceutical therapy is formulated for intraarterial or intravenous administration.

10. The use of any one of claims 1-9, wherein the first pharmaceutical therapy is to be administered at a dosage of from about 60 mg/m^2 and to about 90 mg/m^2.

11. The use of any one of claims 1-10, wherein the first pharmaceutical therapy is to be administered two to four times per week.

12. The use of any one of claims 1-11, wherein the first pharmaceutical therapy is to be administered prior to the administration of the second pharmaceutical therapy.

13. The use of any one of claims 1-11, wherein the first pharmaceutical therapy and the second pharmaceutical therapy are to be administered concurrently.

14. The use of any one of claims 1-11, wherein the second pharmaceutical therapy is to be administered prior to the administration of the first pharmaceutical therapy.

15. The use of any one of claims 1-14, wherein the first pharmaceutical therapy and the second pharmaceutical therapy are to be administered by distinct routes.

16. The use of any one of claims 1-15, wherein the patient is a human.